Format

Send to

Choose Destination
See comment in PubMed Commons below
Drug Discov Today. 2012 Jun;17(11-12):573-82. doi: 10.1016/j.drudis.2012.01.009. Epub 2012 Jan 26.

Targeting neuronal adenylyl cyclase for the treatment of chronic pain.

Author information

1
Department of Physiology, Faculty of Medicine, University of Toronto, Ont, Canada. min.zhuo@utoronto.ca

Abstract

Pain research is currently undergoing dramatic changes. In the area of basic pain research, new discoveries have been made towards the understanding of pain transmission, modulation and plasticity. However, many of these basic discoveries have not yet led to the development of new drugs for the treatment of chronic pain. One major reason for this disconnection is the lack of translational research and drug discovery based directly on the novel pain mechanism. In this review, I focus on activity-dependent potentiation in pain-related cortical areas and recent translational research on adenylyl cyclase subtype 1 (AC1) as a novel target for treating chronic pain. In particular, I discuss the AC1 inhibitor, NB001, which produces powerful analgesic effects in animal models of chronic pain by inhibiting chronic pain-related cortical potentiation.

PMID:
22405897
DOI:
10.1016/j.drudis.2012.01.009
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center